Skip Navigation
Skip to contents

Diabetes Metab J : Diabetes & Metabolism Journal

Search
OPEN ACCESS

Author index

Page Path
HOME > Browse > Author index
Search
Gwanpyo Koh  (Koh G) 6 Articles
Enhancing Patient Outcomes: Prioritizing SGLT2is and GLP-1RAs in Diabetes with CVD
Gwanpyo Koh
Diabetes Metab J. 2024;48(2):208-212.   Published online March 22, 2024
DOI: https://doi.org/10.4093/dmj.2024.0096
  • 1,328 View
  • 180 Download
PDFPubReader   ePub   
Metabolic Risk/Epidemiology
Article image
Current Status of Low-Density Lipoprotein Cholesterol Target Achievement in Patients with Type 2 Diabetes Mellitus in Korea Compared with Recent Guidelines
Soo Jin Yun, In-Kyung Jeong, Jin-Hye Cha, Juneyoung Lee, Ho Chan Cho, Sung Hee Choi, SungWan Chun, Hyun Jeong Jeon, Ho-Cheol Kang, Sang Soo Kim, Seung-Hyun Ko, Gwanpyo Koh, Su Kyoung Kwon, Jae Hyuk Lee, Min Kyong Moon, Junghyun Noh, Cheol-Young Park, Sungrae Kim
Diabetes Metab J. 2022;46(3):464-475.   Published online March 3, 2022
DOI: https://doi.org/10.4093/dmj.2021.0088
  • 7,621 View
  • 365 Download
  • 4 Web of Science
  • 7 Crossref
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
Background
We evaluated the achievement of low-density lipoprotein cholesterol (LDL-C) targets in patients with type 2 diabetes mellitus (T2DM) according to up-to-date Korean Diabetes Association (KDA), European Society of Cardiology (ESC)/European Atherosclerosis Society (EAS), and American Diabetes Association (ADA) guidelines.
Methods
This retrospective cohort study collected electronic medical record data from patients with T2DM (≥20 years) managed by endocrinologists from 15 hospitals in Korea (January to December 2019). Patients were categorized according to guidelines to assess LDL-C target achievement. KDA (2019): Very High-I (atherosclerotic cardiovascular disease [ASCVD]) <70 mg/dL; Very High-II (target organ damage [TOD], or cardiovascular risk factors [CVRFs]) <70 mg/dL; high (others) <100 mg/dL. ESC/EAS (2019): Very High-I (ASCVD): <55 mg/dL; Very High-II (TOD or ≥3-CVRF) <55 mg/dL; high (diabetes ≥10 years without TOD plus any CVRF) <70 mg/dL; moderate (diabetes <10 years without CVRF) <100 mg/dL. ADA (2019): Very High-I (ASCVD); Very High-II (age ≥40+ TOD, or any CVRF), for high intensity statin or statin combined with ezetimibe.
Results
Among 2,000 T2DM patients (mean age 62.6 years; male 55.9%; mean glycosylated hemoglobin 7.2%) ASCVD prevalence was 24.7%. Of 1,455 (72.8%) patients treated with statins, 73.9% received monotherapy. According to KDA guidelines, LDL-C target achievement rates were 55.2% in Very High-I and 34.9% in Very High-II patients. With ESC/EAS guidelines, target attainment rates were 26.6% in Very High-I, 15.7% in Very High-II, and 25.9% in high risk patients. Based on ADA guidelines, most patients (78.9%) were very-high risk; however, only 15.5% received high-intensity statin or combination therapy.
Conclusion
According to current dyslipidemia management guidelines, LDL-C goal achievement remains suboptimal in Korean patients with T2DM.

Citations

Citations to this article as recorded by  
  • Risk factor control and cardiovascular events in patients with type 2 diabetes mellitus
    Do Kyeong Song, Young Sun Hong, Yeon-Ah Sung, Hyejin Lee, Hidetaka Hamasaki
    PLOS ONE.2024; 19(2): e0299035.     CrossRef
  • Distinct effects of rosuvastatin and rosuvastatin/ezetimibe on senescence markers of CD8+ T cells in patients with type 2 diabetes mellitus: a randomized controlled trial
    Sang-Hyeon Ju, Joung Youl Lim, Minchul Song, Ji Min Kim, Yea Eun Kang, Hyon-Seung Yi, Kyong Hye Joung, Ju Hee Lee, Hyun Jin Kim, Bon Jeong Ku
    Frontiers in Endocrinology.2024;[Epub]     CrossRef
  • Monitoring Global Progress in Core Diabetes Control Metrics: Protocol for a Systematic Review of Prevalence (2015–2023)
    John McCaffrey, Samira Barbara Jabakhanji, Roopa Mehta, Steven James, Maisoon Mairghani, Dominika Bhatia, Hazel Ní Chonchubhair, Killian Walsh, Barbara Clyne, Edward W. Gregg
    HRB Open Research.2024; 7: 27.     CrossRef
  • Lipid Management in Korean People With Type 2 Diabetes Mellitus: Korean Diabetes Association and Korean Society of Lipid and Atherosclerosis Consensus Statement
    Ye Seul Yang, Hack-Lyoung Kim, Sang-Hyun Kim, Min Kyong Moon
    Journal of Lipid and Atherosclerosis.2023; 12(1): 12.     CrossRef
  • Lipid Management in Korean People with Type 2 Diabetes Mellitus: Korean Diabetes Association and Korean Society of Lipid and Atherosclerosis Consensus Statement
    Ye Seul Yang, Hack-Lyoung Kim, Sang-Hyun Kim, Min Kyong Moon
    Diabetes & Metabolism Journal.2023; 47(1): 1.     CrossRef
  • Management of Dyslipidemia in Patients with Diabetes Mellitus
    Kyung Ae Lee
    The Journal of Korean Diabetes.2023; 24(3): 111.     CrossRef
  • Association between carotid atherosclerosis and presence of intracranial atherosclerosis using three-dimensional high-resolution vessel wall magnetic resonance imaging in asymptomatic patients with type 2 diabetes
    Ji Eun Jun, You-Cheol Hwang, Kyu Jeong Ahn, Ho Yeon Chung, Geon-Ho Jahng, Soonchan Park, In-Kyung Jeong, Chang-Woo Ryu
    Diabetes Research and Clinical Practice.2022; 191: 110067.     CrossRef
Clinical Diabetes & Therapeutics
Effectiveness and Safety of Adding Basal Insulin Glargine in Patients with Type 2 Diabetes Mellitus Exhibiting Inadequate Response to Metformin and DPP-4 Inhibitors with or without Sulfonylurea
Yu Mi Kang, Chang Hee Jung, Seung-Hwan Lee, Sang-Wook Kim, Kee-Ho Song, Sin Gon Kim, Jae Hyeon Kim, Young Min Cho, Tae Sun Park, Bon Jeong Ku, Gwanpyo Koh, Dol Mi Kim, Byung-Wan Lee, Joong-Yeol Park
Diabetes Metab J. 2019;43(4):432-446.   Published online June 19, 2019
DOI: https://doi.org/10.4093/dmj.2018.0092
  • 5,881 View
  • 95 Download
  • 2 Web of Science
  • 2 Crossref
AbstractAbstract PDFSupplementary MaterialPubReader   
Background

We aimed to investigate the effectiveness and safety of adding basal insulin to initiating dipeptidyl peptidase-4 (DPP-4) inhibitor and metformin and/or sulfonylurea (SU) in achieving the target glycosylated hemoglobin (HbA1c) in patients with type 2 diabetes mellitus (T2DM).

Methods

This was a single-arm, multicenter, 24-week, open-label, phase 4 study in patients with inadequately controlled (HbA1c ≥7.5%) T2DM despite the use of DPP-4 inhibitor and metformin. A total of 108 patients received insulin glargine while continuing oral antidiabetic drugs (OADs). The primary efficacy endpoint was the percentage of subjects achieving HbA1c ≤7.0%. Other glycemic profiles were also evaluated, and the safety endpoints were adverse events (AEs) and hypoglycemia.

Results

The median HbA1c at baseline (8.9%; range, 7.5% to 11.1%) decreased to 7.6% (5.5% to 11.7%) at 24 weeks. Overall, 31.7% subjects (n=33) achieved the target HbA1c level of ≤7.0%. The mean differences in body weight and fasting plasma glucose were 1.2±3.4 kg and 56.0±49.8 mg/dL, respectively. Hypoglycemia was reported in 36 subjects (33.3%, 112 episodes), all of which were fully recovered. There was no serious AE attributed to insulin glargine. Body weight change was significantly different between SU users and nonusers (1.5±2.5 kg vs. −0.9±6.0 kg, P=0.011).

Conclusion

The combination add-on therapy of insulin glargine, on metformin and DPP-4 inhibitors with or without SU was safe and efficient in reducing HbA1c levels and thus, is a preferable option in managing T2DM patients exhibiting dysglycemia despite the use of OADs.

Citations

Citations to this article as recorded by  
  • Glycaemic control with add‐on thiazolidinedione or a sodium‐glucose co‐transporter‐2 inhibitor in patients with type 2 diabetes after the failure of an oral triple antidiabetic regimen: A 24‐week, randomized controlled trial
    Jaehyun Bae, Ji Hye Huh, Minyoung Lee, Yong‐Ho Lee, Byung‐Wan Lee
    Diabetes, Obesity and Metabolism.2021; 23(2): 609.     CrossRef
  • Beneficial effect of anti-diabetic drugs for nonalcoholic fatty liver disease
    Kyung-Soo Kim, Byung-Wan Lee
    Clinical and Molecular Hepatology.2020; 26(4): 430.     CrossRef
Pathophysiology
Factors Related to Blood Intact Incretin Levels in Patients with Type 2 Diabetes Mellitus
Soyeon Yoo, Eun-Jin Yang, Gwanpyo Koh
Diabetes Metab J. 2019;43(4):495-503.   Published online February 20, 2019
DOI: https://doi.org/10.4093/dmj.2018.0105
  • 4,030 View
  • 36 Download
AbstractAbstract PDFPubReader   
Background

We performed this study to identify factors related to intact incretin levels in patients with type 2 diabetes mellitus (T2DM).

Methods

We cross-sectionally analyzed 336 patients with T2DM. Intact glucagon-like peptide 1 (iGLP-1) and intact glucose-dependent insulinotropic polypeptide (iGIP) levels were measured in a fasted state and 30 minutes after ingestion of a standard mixed meal. The differences between 30 and 0 minute iGLP-1 and iGIP levels were indicated as ΔiGLP-1 and ΔiGIP.

Results

In simple correlation analyses, fasting iGLP-1 was positively correlated with glucose, C-peptide, creatinine, and triglyceride levels, and negatively correlated with estimated glomerular filtration rate. ΔiGLP-1 was positively correlated only with ΔC-peptide levels. Fasting iGIP showed positive correlations with glycosylated hemoglobin (HbA1c) and fasting glucose levels, and negative correlations with ΔC-peptide levels. ΔiGIP was negatively correlated with diabetes duration and HbA1c levels, and positively correlated with Δglucose and ΔC-peptide levels. In multivariate analyses adjusting for age, sex, and covariates, fasting iGLP-1 levels were significantly related to fasting glucose levels, ΔiGLP-1 levels were positively related to ΔC-peptide levels, fasting iGIP levels were related to fasting C-peptide levels, and ΔiGIP levels were positively related to ΔC-peptide and Δglucose levels.

Conclusion

Taken together, intact incretin levels are primarily related to C-peptide and glucose levels. This result suggests that glycemia and insulin secretion are the main factors associated with intact incretin levels in T2DM patients.

Changes in Adenosine Deaminase Activity in Patients with Type 2 Diabetes Mellitus and Effect of DPP-4 Inhibitor Treatment on ADA Activity
Jae-Geun Lee, Dong Gu Kang, Jung Re Yu, Youngree Kim, Jinsoek Kim, Gwanpyo Koh, Daeho Lee
Diabetes Metab J. 2011;35(2):149-158.   Published online April 30, 2011
DOI: https://doi.org/10.4093/dmj.2011.35.2.149
  • 4,604 View
  • 34 Download
  • 28 Crossref
AbstractAbstract PDFPubReader   
Background

Dipeptidyl peptidase 4 (DPP-4, also known as CD26) binds with adenosine deaminase (ADA) to activate T lymphocytes. Here, we investigated whether ADA activity is specifically affected by treatment with DPP-4 inhibitor (DPP4I) compared with other anti-diabetic agents.

Methods

Fasting ADA activity, in addition to various metabolic and biochemical parameters, were measured in 262 type 2 diabetes mellitus (T2DM) patients taking various anti-diabetic agents and in 46 non-diabetic control subjects.

Results

ADA activity was increased in T2DM patients compared with that in non-diabetic control subjects (mean±standard error, 23.1±0.6 U/L vs. 18.6±0.8 U/L; P<0.05). ADA activity was correlated with fasting plasma glucose (r=0.258, P<0.05), HbA1c (r=0.208, P<0.05), aspartate aminotransferase (r=0.325, P<0.05), and alanine aminotransferase (r=0.248, P<0.05). Compared with the well-controlled T2DM patients (HbA1c<7%), the poorly controlled group (HbA1c>9%) showed significantly increased ADA activity (21.1±0.8 U/L vs. 25.4±1.6 U/L; P<0.05). The effect of DPP4I on ADA activity in T2DM patients did not differ from those of other oral anti-diabetic agents or insulin. T2DM patients on metformin monotherapy showed a lower ADA activity (20.9±1.0 U/L vs. 28.1±2.8 U/L; P<0.05) compared with that of those on sulfonylurea monotherapy.

Conclusion

Our results show that ADA activity is increased in T2DM patients compared to that in non-diabetic patients, is positively correlated with blood glucose level, and that DPP4I has no additional specific effect on ADA activity, except for a glycemic control- or HbA1c-dependent effect.

Citations

Citations to this article as recorded by  
  • Influence of BMI on adenosine deaminase and stroke outcomes in mechanical thrombectomy subjects
    Benton Maglinger, Christopher J. McLouth, Jacqueline A. Frank, Chintan Rupareliya, Madison Sands, Lila Sheikhi, Shivani Pahwa, David Dornbos, Jordan P. Harp, Amanda L. Trout, Jadwiga Turchan-Cholewo, Ann M. Stowe, Justin F. Fraser, Keith R. Pennypacker
    Brain, Behavior, & Immunity - Health.2022; 20: 100422.     CrossRef
  • Glutamine restores testicular glutathione-dependent antioxidant defense and upregulates NO/cGMP signaling in sleep deprivation-induced reproductive dysfunction in rats
    M.A. Hamed, T.M. Akhigbe, R.E. Akhigbe, A.O. Aremu, P.A. Oyedokun, J.A. Gbadamosi, P.E. Anifowose, M.A. Adewole, O.O. Aboyeji, H.O. Yisau, G.O. Tajudeen, M.M. Titiloye, N.F. Ayinla, A.F. Ajayi
    Biomedicine & Pharmacotherapy.2022; 148: 112765.     CrossRef
  • Effects of quercetin and metabolites on uric acid biosynthesis and consequences for gene expression in the endothelium
    Sarka Tumova, Yuanlu Shi, Ian M. Carr, Gary Williamson
    Free Radical Biology and Medicine.2021; 162: 191.     CrossRef
  • The value of adenosine deaminase activity in latent autoimmune diabetes in adults and type 2 diabetes patients
    Yu Zhou, Wei-Dong Jin, Zhen-Zhen Pang, Jun Xia, Su-Feng Chen
    International Journal of Diabetes in Developing Countries.2021; 41(1): 48.     CrossRef
  • Purinergic signaling in diabetes and metabolism
    Shanu Jain, Kenneth A. Jacobson
    Biochemical Pharmacology.2021; 187: 114393.     CrossRef
  • Berberine modulates crucial erectogenic biomolecules and alters histological architecture in penile tissues of diabetic rats
    Stephen Adeniyi Adefegha, Ganiyu Oboh, Felix Abayomi Dada, Sunday Idowu Oyeleye, Bathlomew Maduka Okeke
    Andrologia.2021;[Epub]     CrossRef
  • Suppression of uric acid and lactate production by sodium acetate ameliorates hepatic triglyceride accumulation in fructose-insulin resistant pregnant rats
    Adewumi O. Oyabambi, Kehinde S. Olaniyi, Ayodele O. Soladoye, Lawrence A. Olatunji
    Environmental Toxicology and Pharmacology.2020; 80: 103452.     CrossRef
  • Therapeutic Perspectives of Adenosine Deaminase Inhibition in Cardiovascular Diseases
    Barbara Kutryb-Zajac, Paulina Mierzejewska, Ewa M. Slominska, Ryszard T. Smolenski
    Molecules.2020; 25(20): 4652.     CrossRef
  • Adenosine as a Marker and Mediator of Cardiovascular Homeostasis: A Translational Perspective
    Trevor Simard, Richard Jung, Alisha Labinaz, Mohammad Ali Faraz, F. Daniel Ramirez, Pietro Di Santo, Ian Pitcher, Pouya Motazedian, Chantal Gaudet, Rebecca Rochman, Jeffrey Marbach, Paul Boland, Kiran Sarathy, Saleh Alghofaili, Juan J. Russo, Etienne Cout
    Cardiovascular & Hematological Disorders-Drug Targets.2019; 19(2): 109.     CrossRef
  • Mineralocorticoid receptor blockade attenuates disrupted glutathione-dependent antioxidant defense and elevated endoglin in the hearts of pregnant rats exposed to testosterone
    Taofeek O. Usman, Olufunto O. Badmus, InKyeom Kim, Lawrence A. Olatunji
    Naunyn-Schmiedeberg's Archives of Pharmacology.2019; 392(7): 773.     CrossRef
  • Serum activities of dipeptidyl peptidase-4 and adenosine deaminase in polycystic ovary syndrome: association with obesity
    Seda Kahraman, Alev Eroglu Altinova, Serenay Elgun, Mehmet Muhittin Yalcin, Banu Aktas Yilmaz, Cigdem Ozkan, Mujde Akturk, Fusun Balos Toruner
    Gynecological Endocrinology.2019; 35(8): 714.     CrossRef
  • Serum adenosine deaminase activity and coronary artery disease: a retrospective case-control study based on 9929 participants
    Chao Xuan, Qing-Wu Tian, Shao-Yan Zhang, Hui Li, Ting-Ting Tian, Peng Zhao, Kang Yue, Yan-Yan Ling, Guo-Wei He, Li-Min Lun
    Therapeutic Advances in Chronic Disease.2019; 10: 204062231989153.     CrossRef
  • Metabolites related to purine catabolism and risk of type 2 diabetes incidence; modifying effects of the TCF7L2-rs7903146 polymorphism
    Christopher Papandreou, Jun Li, Liming Liang, Mònica Bulló, Yan Zheng, Miguel Ruiz-Canela, Edward Yu, Marta Guasch-Ferré, Cristina Razquin, Clary Clish, Dolores Corella, Ramon Estruch, Emilio Ros, Montserrat Fitó, Fernando Arós, Lluís Serra-Majem, Nuria R
    Scientific Reports.2019;[Epub]     CrossRef
  • Current status of G-protein coupled receptors as potential targets against type 2 diabetes mellitus
    Mehboob Hoque, Safdar Ali, Muddasarul Hoda
    International Journal of Biological Macromolecules.2018; 118: 2237.     CrossRef
  • Endoglin inhibition by sodium acetate and flutamide ameliorates cardiac defective G6PD-dependent antioxidant defense in gestational testosterone-exposed rats
    Lawrence A. Olatunji, Emmanuel D. Areola, Olufunto O. Badmus
    Biomedicine & Pharmacotherapy.2018; 107: 1641.     CrossRef
  • Sodium acetate and androgen receptor blockade improve gestational androgen excess-induced deteriorated glucose homeostasis and antioxidant defenses in rats: roles of adenosine deaminase and xanthine oxidase activities
    Taofeek O. Usman, Emmanuel D. Areola, Olufunto O. Badmus, InKyeom Kim, Lawrence A. Olatunji
    The Journal of Nutritional Biochemistry.2018; 62: 65.     CrossRef
  • ADENOSINE DEAMINASE ACTIVITY IN TYPE 2 DIABETES MELLITUS
    Farija Peruvankuzhiyil, Lavanya Madhavan, Manaloor George Joseraj
    Journal of Evidence Based Medicine and Healthcare.2017; 4(5): 238.     CrossRef
  • Adenosine signaling in diabetes mellitus and associated cardiovascular and renal complications
    Maria Peleli, Mattias Carlstrom
    Molecular Aspects of Medicine.2017; 55: 62.     CrossRef
  • The Adenosinergic System in Diabetic Retinopathy
    J. Vindeirinho, A. R. Santiago, C. Cavadas, A. F. Ambrósio, P. F. Santos
    Journal of Diabetes Research.2016; 2016: 1.     CrossRef
  • Upregulation of inducible NO synthase by exogenous adenosine in vascular smooth muscle cells activated by inflammatory stimuli in experimental diabetes
    Alberto Nassi, Francesca Malorgio, Serena Tedesco, Andrea Cignarella, Rosa Maria Gaion
    Cardiovascular Diabetology.2016;[Epub]     CrossRef
  • Reduced adenosine A2a receptor–mediated efferent arteriolar vasodilation contributes to diabetes-induced glomerular hyperfiltration
    Patrik Persson, Peter Hansell, Fredrik Palm
    Kidney International.2015; 87(1): 109.     CrossRef
  • CD26/DPP4 Levels in Peripheral Blood and T Cells in Patients With Type 2 Diabetes Mellitus
    Sang Ah Lee, Young Ree Kim, Eun Jin Yang, Eun-Jeong Kwon, Sun Hyung Kim, Sung Ha Kang, Doek Bae Park, Byung-Chul Oh, Jinseok Kim, Sang Taek Heo, Gwanpyo Koh, Dae Ho Lee
    The Journal of Clinical Endocrinology & Metabolism.2013; 98(6): 2553.     CrossRef
  • Raised Serum Adenosine Deaminase Level in Nonobese Type 2 Diabetes Mellitus
    Vineet Kumar Khemka, Debajit Bagchi, Arindam Ghosh, Oishimaya Sen, Aritri Bir, Sasanka Chakrabarti, Anindita Banerjee, R. E. Felberbaum, V. Sánchez-Margalet, S. Ulisse
    The Scientific World Journal.2013;[Epub]     CrossRef
  • Phosphodiesterase III Inhibition Increases cAMP Levels and Augments the Infarct Size Limiting Effect of a DPP-4 Inhibitor in Mice with Type-2 Diabetes Mellitus
    Yochai Birnbaum, Alexander C. Castillo, Jinqiao Qian, Shukuan Ling, Hongmei Ye, Jose R. Perez-Polo, Mandeep Bajaj, Yumei Ye
    Cardiovascular Drugs and Therapy.2012; 26(6): 445.     CrossRef
  • Serum Adenosine deaminase activity in type 2 Diabetes Mellitus patients
    M. N. Vanitha Gowda, K. C. Vasudha, S. Reshma, K. J. Sujatha
    International Journal of Diabetes in Developing Countries.2012; 32(3): 176.     CrossRef
  • Cyclic AMP and PKA: How can a Lot of Good Come from the Potentially Bad?
    Barbara Huisamen
    Cardiovascular Drugs and Therapy.2012; 26(6): 435.     CrossRef
  • Gadd45α: A Novel Diabetes-Associated Gene Potentially Linking Diabetic Cardiomyopathy and Baroreflex Dysfunction
    Ning Wang, Chao Yang, Fang Xie, Lihua Sun, Xiaolin Su, Ying Wang, Ran Wei, Rong Zhang, Xia Li, Baofeng Yang, Jing Ai, Rajesh Gopalrao Katare
    PLoS ONE.2012; 7(12): e49077.     CrossRef
  • The CD39-Adenosinergic Axis in the Pathogenesis of Immune and Nonimmune Diabetes
    Joanne S. J. Chia, Jennifer L. McRae, Peter J. Cowan, Karen M. Dwyer
    Journal of Biomedicine and Biotechnology.2012; 2012: 1.     CrossRef
Clinical Characteristics of Type 2 Diabetes Patients according to Family History of Diabetes
Seung Uk Jeong, Dong Gu Kang, Dae Ho Lee, Kang Woo Lee, Dong-Mee Lim, Byung Joon Kim, Keun-Yong Park, Hyoun-Jung Chin, Gwanpyo Koh
Korean Diabetes J. 2010;34(4):222-228.   Published online August 31, 2010
DOI: https://doi.org/10.4093/kdj.2010.34.4.222
  • 3,847 View
  • 28 Download
  • 15 Crossref
AbstractAbstract PDFPubReader   
Background

Type 2 diabetes mellitus (T2DM) has a strong genetic component, and its prevalence is notably increased in the family members of T2DM patients. However, there are few studies about the family history of T2DM. We carried out this study to assess the influences of family history on clinical characteristics in T2DM patients.

Methods

This is a cross-sectional study involving 651 T2DM patients. Patient history and physical examination were performed and fasting blood was taken. If any first degree relative was diabetic, a family history of diabetes was considered to exist.

Results

Among the total 621 patients, 38.4% had a family history of diabetes. Patients with a family history had a younger age, higher weight, younger age at diagnosis and higher triglyceride level than did those without a family history. Dyslipidemia medication and metabolic syndrome were more prevalent in familial diabetes. Sex, blood pressure, previous treatment for diabetes, HbA1c, C-peptide, total cholesterol, high density lipoprotein cholesterol, and low density lipoprotein cholesterol were not different between familial and non-familial diabetes. Upon multiple linear regression analysis, the family history of diabetes remained significantly associated with serum triglyceride level.

Conclusion

In T2DM patients with a family history of diabetes, the disease tended to develop earlier. Metabolic syndrome and cardiovascular risk factors are more prevalent in familial T2DM than they were in non-familial T2DM. These results support the necessity of earlier screening for diabetes in family members of T2DM patients and more active prevention against cardiovascular disease in T2DM patients with a family history.

Citations

Citations to this article as recorded by  
  • COVID-19-Induced Diabetes Mellitus: Comprehensive Cellular and Molecular Mechanistic Insights
    Praise Tatenda Nhau, Mlindeli Gamede, Ntethelelo Sibiya
    Pathophysiology.2024; 31(2): 197.     CrossRef
  • Evolutionary algorithm for the optimization of meal intake and insulin administration in patients with type 2 diabetes
    Eva Gonzalez-Flo, Elaheh Kheirabadi, Carlos Rodriguez-Caso, Javier Macía
    Frontiers in Physiology.2023;[Epub]     CrossRef
  • Role of Cytokines (IL-17 and IL-33), FGF-18, and WNT-5 in the Pathogenesis of Patients with Established Type II Diabetes
    Przha Mohammed, Kawa Amin
    Journal of Zankoy Sulaimani - Part A.2023; 25(2): 11.     CrossRef
  • Cellular Chitchatting: Exploring the Role of Exosomes as Cardiovascular Risk Factors
    Giulia Germena, Laura Cecilia Zelarayán, Rabea Hinkel
    Frontiers in Cell and Developmental Biology.2022;[Epub]     CrossRef
  • Combined associations of family history and self-management with age at diagnosis and cardiometabolic risk in 86,931 patients with type 2 diabetes: Joint Asia Diabetes Evaluation (JADE) Register from 11 countries
    Johnny T. K. Cheung, Eric Lau, Cyrus C. T. Tsui, Edmond L. N. Siu, Naomi K. W. Tse, Nicole Y. L. Hui, Ronald C. W. Ma, Alice P. S. Kong, Amy Fu, Vanessa Lau, Weiping Jia, Wayne H. H. Sheu, Leorino Sobrepena, K. H. Yoon, Alexander T. B. Tan, Yook-Chin Chia
    BMC Medicine.2022;[Epub]     CrossRef
  • Capsaicin, its clinical significance in patients with painful diabetic neuropathy
    Phiwayinkosi V. Dludla, Bongani B. Nkambule, Ilenia Cirilli, Fabio Marcheggiani, Sihle E. Mabhida, Khanyisani Ziqubu, Yonela Ntamo, Babalwa Jack, Tawanda M. Nyambuya, Sidney Hanser, Sithandiwe E. Mazibuko-Mbeje
    Biomedicine & Pharmacotherapy.2022; 153: 113439.     CrossRef
  • Safety profile of sodium glucose co-transporter 2 (SGLT2) inhibitors: A brief summary
    Annamaria Mascolo, Raffaella Di Napoli, Nunzia Balzano, Donato Cappetta, Konrad Urbanek, Antonella De Angelis, Lucia Scisciola, Irene Di Meo, Maria Giuseppa Sullo, Concetta Rafaniello, Liberata Sportiello
    Frontiers in Cardiovascular Medicine.2022;[Epub]     CrossRef
  • Impact of triglycerides and waist circumference on insulin resistance and β-cell function in non-diabetic first-degree relatives of type 2 diabetes
    Fahd Ahmed, Molham AL-Habori, Ebtesam Al-Zabedi, Riyadh Saif-Ali
    BMC Endocrine Disorders.2021;[Epub]     CrossRef
  • Orientin Improves Substrate Utilization and the Expression of Major Genes Involved in Insulin Signaling and Energy Regulation in Cultured Insulin-Resistant Liver Cells
    Sithandiwe E. Mazibuko-Mbeje, Sinenhlanhla X. H. Mthembu, Andani Tshiitamune, Ndivhuwo Muvhulawa, Fikile T. Mthiyane, Khanyisani Ziqubu, Christo J. F. Muller, Phiwayinkosi V. Dludla
    Molecules.2021; 26(20): 6154.     CrossRef
  • Identification of Pre-Diabetic Biomarkers in the Progression of Diabetes Mellitus
    Jae-Ho Lee, Do-Young Kim, Rubee Pantha, Eun-Ho Lee, Jae-Hoon Bae, Eugene Han, Dae-Kyu Song, Taeg Kyu Kwon, Seung-Soon Im
    Biomedicines.2021; 10(1): 72.     CrossRef
  • Shared (epi)genomic background connecting neurodegenerative diseases and type 2 diabetes
    Valerio Caputo, Andrea Termine, Claudia Strafella, Emiliano Giardina, Raffaella Cascella
    World Journal of Diabetes.2020; 11(5): 155.     CrossRef
  • Family history of diabetes in both parents is strongly associated with impaired residual β‐cell function in Japanese type 2 diabetes patients
    Minoru Iwata, Yutaka Kamura, Hisae Honoki, Kaori Kobayashi, Manabu Ishiki, Kunimasa Yagi, Yasuo Fukushima, Atsuko Takano, Hiromi Kato, Shihou Murakami, Kiyohiro Higuchi, Chikaaki Kobashi, Kazuhito Fukuda, Yukiko Koshimizu, Kazuyuki Tobe
    Journal of Diabetes Investigation.2020; 11(3): 564.     CrossRef
  • The relationship between age of onset and risk factors including family history and life style in Korean population with type 2 diabetes mellitus
    Jin-Won Noh, Jin Hee Jung, Jeong Eun Park, Jung Hwa Lee, Kang Hee Sim, Jumin Park, Min Hee Kim, Ki-Bong Yoo
    Journal of Physical Therapy Science.2018; 30(2): 201.     CrossRef
  • Clinical Characteristics of Subjects with Sulfonylurea-Dependent Type 2 Diabetes
    Se Hee Min, Soo Heon Kwak, Young Min Cho, Kyong Soo Park, Hye Seung Jung
    Endocrinology and Metabolism.2015; 30(4): 509.     CrossRef
  • Nutritional Assessment of Type II Diabetic Patients
    El-Sayed H. Bakr
    Pakistan Journal of Nutrition.2015; 14(6): 308.     CrossRef

Diabetes Metab J : Diabetes & Metabolism Journal
Close layer